インディアナ州における過体重の臨床試験
インディアナ州内の拠点で、過体重に関する16件の研究が参加者を募集しています。
インディアナ州内の都市
公式研究テキスト（英語）
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- IU Health - Riley Physicians Endo-Diab, Indianapolis
被験者募集中第3相
8歳〜18歳 · 全性別 · 2026/09/30更新 · NCT07253285AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Midwest Inst For Clin Res, Indianapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Midwest Inst For Clin Res, Indianapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- MediSphere Medical Research Center, LLC, Evansville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Riley Hospital for Children, Indianapolis
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Cardiovascular Research of Northwest Indiana LLC, Munster
- Velocity Clinical Research - Valparaiso, Valparaiso
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Qualmedica Research, LLC, Evansville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- DM Clinical Research - Indianapolis, Indianapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07282600A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Evansville
- AURORA-1 Clinical Site, Indianapolis
- AURORA-1 Clinical Site, Valparaiso
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Evansville
- AURORA-2 Clinical Site, Indianapolis
- AURORA-2 Clinical Site, Valparaiso
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Investigators Research Group, Brownsburg
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT06897475A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Midwest Inst For Clin Res, Indianapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07745504A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06857942Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- Indiana University, Indianapolis
被験者募集中
18歳〜45歳 · 女性 · 2026/06/24更新 · NCT05124808ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。